CliffBio
biologic

ADZYNMA

ADAMTS13, recombinant-krhn

Loss of exclusivityNovember 2035projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameADZYNMA
Active ingredientADAMTS13, recombinant-krhn
Strength500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2023
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

ADZYNMA patent cliff — loss of exclusivity November 2035 | CliffBio